Top

Reviews in Endocrine and Metabolic Disorders

Published in:

01-06-2009

Medical therapy of pituitary adenomas: Effects on tumor shrinkage

Authors: Annamaria Colao, Rosario Pivonello, Carolina Di Somma, Silvia Savastano, Ludovica F. S. Grasso, Gaetano Lombardi

Published in: Reviews in Endocrine and Metabolic Disorders | Issue 2/2009

Abstract

The efficacy of dopamine-agonists (DA) in patients with prolactinomas and that of somatostatin analogues (SSA) in those with GH- and TSH-secreting adenomas is well established. More recently, data are accumulating suggesting a potential therapeutic role of DA also in patients with ACTH-secreting and clinically non-functioning (NFA) pituitary adenomas. This review aims at summarizing published results of DA and SSA on tumor shrinkage in patients with different histotypes of pituitary adenomas. Results of tumor shrinkage are of clinical relevance as tumor size is the one of the most important determinant of surgical outcome. While reduction of tumor size more than 50% of baseline size in macroprolactinomas treated with DA is a frequent finding in patients with GH-secreting adenomas treated with SSA tumor shrinkage only recently is becoming frequent thanks to the availability of depot formulations. Data on tumor shrinkage in patients with TSH-secreting adenomas treated with SSA are limited because of the rarity of these tumors. Very recently, DA have been reported of some efficacy also in patients with ACTH-secreting adenomas but data are still very limited. NFA respond very scantly to both DA and SSA even if receptors targeting these drugs are present. Whether this is due to limited receptor number or alterations of post-receptor pathway is still unknown.

Gillam MP, Molitch ME, Lombardi G, Colao A. Advances in the treatment of prolactinomas. Endocr Rev. 2006;27:485–534. doi:10.1210/er.2005-9998.PubMed

Melmed S, Casanueva FF, Cavagnini F, Chanson P, Frohman L, Grossman A, Acromegaly Treatment Consensus Workshop Participants, et al. Guidelines for acromegaly management. J Clin Endocrinol Metab 2002;87:4054–8. doi:10.1210/jc.2002-011841.PubMed

Caron P, Arlot S, Bauters C, Chanson P, Kuhn JM, Pugeat M, et al. Efficacy of the long-acting octreotide formulation (octreotide-LAR) in patients with thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 2001;86:2849–53. doi:10.1210/jc.86.6.2849.PubMed

Missale C, Nash SR, Robinson SW, Jaber M, Caron MG. Dopamine receptors: from structure to function. Physiol Rev. 1998;78:189–225.PubMed

Caccavelli L, Cussac D, Pellegrini I, Audinot V, Jaquet P, Enjalbert A. D2 dopaminergic receptors: normal and abnormal transduction mechanisms. Horm Res. 1992;38:78–83.PubMed

Giros B, Sokoloff P, Martres MP, Riou JF, Emorine LJ, Schwartz JC. Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 1989;342:923–6. doi:10.1038/342923a0.PubMed

Spada A, Nicosia S, Cortelazzi L, Pezzo G, Bassetti M, Sartorio A, et al. In vitro studies on prolactin release and adenylate cyclase activity in human prolactin-secreting pituitary adenomas. Different sensitivity of macro- and microadenomas to dopamine and vasoactive intestinal polypeptide. J Clin Endocrinol Metab. 1983;56:1–10.PubMed

Bevan JS, Webster J, Burke CW, Scanlon MF. Dopamine agonists and pituitary tumor shrinkage. Endocr Rev. 1992;13:220–40. doi:10.1210/er.13.2.220.PubMed

Trouillas J, Chevallier P, Claustrat B, Hooghe-Peters E, Dubray C, Rousset B, et al. Inhibitory effects of the dopamine agonists quinagolide (CV 205–502) and bromocriptine on prolactin secretion and growth of SMtTW pituitary tumors in the rat. Endocrinology. 1994;134:401–10. doi:10.1210/en.134.1.401.PubMed

10.

Hofland LJ, Lamberts SWJ. Somatostatin receptor subtype expression in human tumors. Ann Oncol. 2001;12(Suppl 2):S31–6. doi:10.1023/A:1012420207244.PubMed

11.

Culler MD, Taylor JE, Moreau JP. Somatostatin receptor subtypes: targeting functional and therapeutic specificity. Ann Endocrinol. 2002;63:2S5–2S12.

12.

Ferjoux G, Bousquet C, Cordelier P, Benali N, Lopez F, Rochaix P, et al. Signal transduction of somatostatin receptors negatively controlling cell proliferation. J Physiol. 2000;94:205–10.

13.

Guillermet Guibert J, Lahlou H, Cordelier P, Bousquet C, Pyronnet S, Susini C. Physiology of somatostatin receptors. JEI 2005;28(11 Suppl International):5–9.

14.

Garcıa de la Torre N, Wass JAH, Turner HE. Antiangiogenic effects of somatostatin analogues. Clin Endocrinol (Oxf). 2002;57:425–41. doi:10.1046/j.1365-2265.2002.01619.x.

15.

Losa M, Ciccarelli E, Mortini P, Barzaghi R, Gaia D, Faccani G, et al. Effects of octreotide treatment on the proliferation and apoptotic index of GH-secreting pituitari adenomas. J Clin Endocrinol Metab. 2001;86:5194–200. doi:10.1210/jc.86.11.5194.PubMed

16.

Thapar K, Kovacs KT, Stefaneanu L, Scheithauer BW, Horvath E, Lloyd RV, et al. Antiproliferative effect of the somatostatin analogue octreotide on growth hormone-producing pituitary tumors: results of a multicentre randomized trial. Mayo Clin Proc. 1997;72:893–900.PubMed

17.

Ezzat S, Horvath E, Harris AG, Kovacs K. Morphological effects of octreotide on growth hormone-producing pituitary adenomas. J Clin Endocrinol Metab. 1994;79:113–8. doi:10.1210/jc.79.1.113.PubMed

18.

Colao A, di Sarno A, Pivonello R, di Somma C, Lombardi G. Dopamine receptor agonists for treating prolactinomas. Expert Opin Investig Drugs. 2002;11:787–800. doi:10.1517/13543784.11.6.787.PubMed

19.

Lamberts SWJ, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334:246–54. doi:10.1056/NEJM199601253340408.PubMed

20.

Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab. 2002;87:3013–8. doi:10.1210/jc.87.7.3013.PubMed

21.

Colao A, Marzullo P, Ferone D, Marinò V, Pivonello R, Di Somma C, et al. Effectiveness and tolerability of slow release lanreotide treatment in active acromegaly. J Endocrinol Invest. 1999;22:40–7.PubMed

22.

Lancranjan I, Bruns C, Grass P, Jaquet P, Jarvell J, Kendall-Taylor P, et al. Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism. 1996;45(Suppl 1):67–71. doi:10.1016/S0026-0495(96)90087-6.PubMed

23.

McKeage K, Cheer A, Wagstaff AJ. Octreotide Long-Acting Release (LAR). A review of its use in the management of acromegaly. Drugs. 2003;63:2473–99. doi:10.2165/00003495-200363220-00014.PubMed

24.

Colao A, Pivonello R, Auriemma RS, Galdiero M, Savastano S, Lombardi G. Beneficial effect of dose escalation of octreotide-LAR as first-line therapy in patients with acromegaly. Eur J Endocrinol. 2007;157(5):579–87. doi:10.1530/EJE-07-0383.PubMed

25.

Caron P, Cogne M, Raingeard I, Bex-Bachellerie V, Kuhn JM. Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clin Endocrinol (Oxf). 2006;64:209–14. doi:10.1111/j.1365-2265.2006.02450.x.

26.

Lombardi G, Minuto F, Tamburrano G, Ambrosio MR, Arnaldi G, Arosio M, et al. Efficacy of the new long-acting formulation of lanreotide (Lanreotide Autogel) in somatostatin analogues naive patients with acromegaly. J Endocrinol Invest. 2008; In press.

27.

Bruns C, Lewis I, Briner U, et al. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. Eur J Endocrinol. 2002;146:707–16. doi:10.1530/eje.0.1460707.PubMed

28.

van der Hoek J, de Herder WW, Feelders RA, van der Lely AJ, Uitterlinden P, Boerlin V, et al. A single-dose comparison of the acute effects between the new somatostatin analog SOM 230 and octreotide in acromegalic patients. J Clin Endocrinol Metab. 2004;89:638–45. doi:10.1210/jc.2003-031052.PubMed

29.

Fedele M, De Martino I, Pivonello R, Ciarmiello A, Del Basso De Caro ML, Visone R, et al. SOM230, A New Somatostatin Analogue, Is Highly Effective in the Therapy of Growth Hormone/Prolactin-Secreting Pituitary Adenomas. Clin Cancer Res. 2007;13:2738–44. doi:10.1158/1078-0432.CCR-06-2505.PubMed

30.

Colao A, Lombardi G, Annunziato L. Cabergoline. Expert Opin Pharmacother. 2000;1:555–74. doi:10.1517/14656566.1.3.555.PubMed

31.

Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B, et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518–22. doi:10.1210/jc.84.7.2518.PubMed

32.

Colao A, Di Sarno A, Landi ML, Cirillo S, Sarnacchiaro F, Facciolli G, et al. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab. 1997;82:3574–9. doi:10.1210/jc.82.11.3574.PubMed

33.

Colao A, Di Sarno A, Landi ML, Scavuzzo F, Cappabianca P, Pivonello R, et al. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients. J Clin Endocrinol Metab. 2000;85:2247–52. doi:10.1210/jc.85.6.2247.PubMed

34.

Di Sarno A, Landi ML, Cappabianca P, Di Salle F, Rossi FW, Pivonello R, et al. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy. J Clin Endocrinol Metab. 2001;86:5256–61. doi:10.1210/jc.86.11.5256.PubMed

35.

Colao A, De Rosa M, Sarnacchiaro F, Di Sarno A, Landi ML, Iervolino E, et al. Chronic treatment with CV 205–502 restores the gonadal function in hyperprolactinemia males. Eur J Endocrinol. 1996;135:548–52.PubMed

36.

Vance ML, Lipper M, Klibanski A, Biller BM, Samaan NA, Molitch ME. Treatment of prolactin-secreting pituitary macroadenomas with the long-acting non-ergot dopamine agonist CV 205–502. Ann Intern Med. 1990;112:668–73.PubMed

37.

Cannavo S, Bartolone L, Blandino A, Spinella S, Galatioto S, Trimarchi F. Shrinkage of a PRL-secreting pituitary macroadenoma resistant to cabergoline. J Endocrinol Invest. 1999;22:306–9.PubMed

38.

Cappabianca P, Lodrini S, Felisati G, Peca C, Cozzi R, Di Sarno A, et al. Cabergoline-induced CSF rhinorrhea in patients with macroprolactinoma. Report of three cases. J Endocrinol Invest. 2001;24:183–7.PubMed

39.

Colao A, Di Sarno A, Cappabianca P, Di Somma C, Pivonello R, Lombardi G. Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med. 2003;349:2023–33. doi:10.1056/NEJMoa022657.PubMed

40.

Fusco A, Gunz G, Jaquet P, Dufour H, Germanetti AL, Culler MD, et al. Somatostatinergic ligands in dopamine-sensitive and -resistant prolactinomas. Eur J Endocrinol. 2008;158:595–603. doi:10.1530/EJE-07-0806.PubMed

41.

Jaffe CA, Barkan AI. Acromegaly: recognition and treatment. Drugs. 1994;47:425–45.PubMed

42.

Colao A, Ferone D, Marzullo P, Di Sarno A, Cerbone G, Sarnacchiaro F, et al. Effect of different dopaminergic agents in the treatment of acromegaly. J Clin Endocrinol Metab. 1997;82:518–23. doi:10.1210/jc.82.2.518.PubMed

43.

Abs R, Versholst J, Maiter D, Van Acker K, Nobels F, Coolens JL, et al. Cabergoline in the treatment of acromegaly: a study in 64 patients. J Clin Endocrinol Metab. 1998;83:374–8. doi:10.1210/jc.83.2.374.PubMed

44.

Cozzi R, Attanasio R, Barausse M, Dallabonzana D, Orlandi P, Da Re N, et al. Cabergoline in acromegaly: a renewed role for dopamine agonist treatment? Eur J Endocrinol. 1998;139:516–21. doi:10.1530/eje.0.1390516.PubMed

45.

Ferrari C, Paracchi A, Romano C, Gerevini G, Boghen M, Barreca A, et al. Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. Clin Endocrinol (Oxf). 1988;29:467–76. doi:10.1111/j.1365-2265.1988.tb03695.x.

46.

Muratori M, Arosio M, Gambino G, Romano C, Biella O, Faglia G. Use of cabergoline in the long-term treatment of hyperprolactinemia and acromegalic patients. J Endocrinol Invest. 1997;20:537–46.PubMed

47.

Rickels MR, Snyder PJ. Cabergoline decreases somatotroph adenoma size: a case report. Pituitary. 2004;7:107–10. doi:10.1007/s11102-005-5353-1.PubMed

48.

Vilar L, Czepielewsk MA, Naves LA, Rollin GA, Casulari LA, Coelho CE. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract. 2007;13:396–402.PubMed

49.

Colao A, Filippella M, Pivonello R, Di Somma C, Faggiano A, Lombardi G. Combined therapy of somatostatin analogues and dopamine agonists in the treatment of pituitary tumours. Eur J Endocrinol. 2007;156(Suppl 1):S57–63. doi:10.1530/eje.1.02348.PubMed

50.

Bevan JS. The antitumoral effects of somatostatin analog therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:1856–63. doi:10.1210/jc.2004-1093.PubMed

51.

Melmed S, Sternberg R, Cook D, Klibanski A, Chanson P, Bonert V, et al. A critical analysis of pituitary tumor shrinkage during primary medical therapy in acromegaly. J Clin Endocrinol Metab. 2005;90:4405–10. doi:10.1210/jc.2004-2466.PubMed

52.

Colao A, Pivonello R, Auriemma RS, Briganti F, Galdiero M, Tortora F, et al. Predictors of tumor shrinkage after primary therapy with somatostatin analogues in acromegaly: a prospective study in 99 patients. J Clin Endocrinol Metab. 2006;91:2112–8. doi:10.1210/jc.2005-2110.PubMed

53.

Murray RD, Melmed S. A critical analysis of clinically available somatostatin analog formulations for therapy of acromegaly. J Clin Endocrinol Metab. 2008;93:2957–68.PubMed

54.

Maiza JC, Vezzosi D, Matta M, Donadille F, Loubes-Lacroix F, Cournot M, et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf). 2007;67:282–9. doi:10.1111/j.1365-2265.2007.02878.x.

55.

Cozzi R, Montini M, Attanasio R, Albizzi M, Lasio G, Lodrini S, et al. Primary treatment of acromegaly with octreotide LAR: a long-term (up to nine years) prospective study of its efficacy in the control of disease activity and tumor shrinkage. J Clin Endocrinol Metab. 2006;91:1397–403. doi:10.1210/jc.2005-2347.PubMed

56.

57.

Resmini E, Dadati P, Ravetti JL, Zona G, Spaziante R, Saveanu A, et al. Rapid pituitary tumor shrinkage with dissociation between antiproliferative and antisecretory effects of a long-acting octreotide in an acromegalic patient. J Clin Endocrinol Metab. 2007;92:1592–9. doi:10.1210/jc.2006-2084.PubMed

58.

Casarini AP, Pinto EM, Jallad RS, Giorgi RR, Giannella-Neto D, Bronstein MD. Dissociation between tumor shrinkage and hormonal response during somatostatin analog treatment in an acromegalic patient: preferential expression of somatostatin receptor subtype 3. J Endocrinol Invest. 2006;29:826–30.PubMed

59.

Besser GM, Burman P, Daly AF. Predictors and rates of treatment-resistant tumor growth in acromegaly. Eur J Endocrinol. 2005;153:187–93. doi:10.1530/eje.1.01968.PubMed

60.

Ferone D, de Herder WW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab. 2008;93:1412–7. doi:10.1210/jc.2007-1358.PubMed

61.

Beck-Peccoz P, Brucker-Davis F, Persani L, Smallridge RC, Weintraub BD. Thyrotropin-secreting pituitary tumours. Endocr Rev. 1996;17:610–38. doi:10.1210/er.17.6.610.PubMed

62.

Kienitz T, Quinkler M, Strasburger CJ, Ventz M. Long-term management in five cases of TSH-secreting pituitary adenomas: a single center study and review of the literature. Eur J Endocrinol. 2007;157:39–46. doi:10.1530/EJE-07-0098.PubMed

63.

Warnet A, Lajeunie E, Gelbert F, Duet M, Chanson P, Cophignon J, et al. Shrinkage of a primary thyrotropin-secreting pituitary adenoma treated with the long-acting somatostatin analogue octreotide (SMS 201–995). Acta Endocrinol (Copenh). 1991;124:487–91.

64.

Wemeau L, Dewailly D, Leroy R, D'Herbomez M, Mazzuca M, Decoulx M, et al. Long term treatment with a somatostatin analog SMS 201–995 in a patient with a thyrotropin and growth hormone-secreting pituitary adenoma. J Clin Endocrinol Metab. 1988;66:636–9.PubMed

65.

Losa M, Giovanelli M, Persani L, Mortini P, Faglia G, Beck-Peccoz P. Criteria of cure and follow-up of central hyperthyroidism due to thyrotropin-secreting pituitary adenomas. J Clin Endocrinol Metab. 1996;81:3084–90. doi:10.1210/jc.81.8.3084.PubMed

66.

Chanson P, Weintraub BD, Harris AG. Treatment of TSH-secreting pituitary adenomas with octreotide: a follow-up of 52 patients. Ann Intern Med. 1993;119:236–40.PubMed

67.

Fischler MP, Reinhart WH. TSH-secreting pituitary macroadenoma: rapid tumor shrinkage and recovery from hyperthyroidism with octreotide. J Endocrinol Invest. 1999;22:64–5.PubMed

68.

Colao A, Filippella M, Di Somma C, Manzi S, Rota F, Pivonello R, et al. Somatostatin analogs in treatment of non-growth hormone-secreting pituitary adenomas. Endocrine. 2003;20:279–83. doi:10.1385/ENDO:20:3:279.PubMed

69.

Gancel A, Vuillermet P, Legrand A, Catus F, Thomas F, Kuhn JM. Effects of a slow-release formulation of the new somatostatin analogue lanreotide in TSH-secreting pituitary adenomas. Clin Endocrinol (Oxf). 1994;40:421–8.

70.

Kuhn JM, Arlot S, Lefebvre H, Caron P, Cortet-Rudelli C, Archambaud F, et al. Evaluation of the treatment of thyrotropin-secreting pituitary adenomas with a slow release formulation of the somatostatin analog lanreotide. J Clin Endocrinol Metab. 2000;85:1487–91. doi:10.1210/jc.85.4.1487.PubMed

71.

72.

Pivonello R, De Martino MC, De Leo M, Lombardi G, Colao A. Cushing’s syndrome. Endocrinol Metab Clin North Am. 2008;37:135–49. doi:10.1016/j.ecl.2007.10.010.PubMed

73.

Biller BM, Grossman AB, Stewart PM, Melmed S, Bertagna X, Bertherat J, et al. Treatment of ACTH-dependent Cushing’s syndrome: a consensus statement. J Clin Endocrinol Metab. 2008;93:2454–62.PubMed

74.

Pivonello R, Ferone D, de Herder WW, Kros JM, De Caro ML, Arvigo M, et al. Dopamine receptor expression and function in corticotroph pituitary tumors. J Clin Endocrinol Metab. 2004;89:2452–62. doi:10.1210/jc.2003-030837.PubMed

75.

Pivonello R, Ferone D, de Herder WW, Faggiano A, Bodei L, de Krijger RR, et al. Dopamine receptor expression and function in corticotroph ectopic tumors. J Clin Endocrinol Metab. 2007;92:65–9. doi:10.1210/jc.2006-0728.PubMed

76.

Pivonello R, Ferone D, de Herder WW, de Krijger RR, Waaijers M, Mooij DM, et al. Dopamine receptor expression and function in human normal adrenal gland and adrenal tumors. J Clin Endocrinol Metab. 2004;89:4493–502. doi:10.1210/jc.2003-031746.PubMed

77.

Miller JW, Crapo L. The medical treatment of Cushing’s syndrome. Endocr Rev. 1993;14:443–58. doi:10.1210/er.14.4.443.PubMed

78.

Pivonello R, Faggiano A, Di Salle F, Filippella M, Lombardi G, Colao A. Complete remission of Nelson’s syndrome after 1-year treatment with cabergoline. J Endocrinol Invest. 1999;22:860–5.PubMed

79.

Hofland LJ, van der Hoek J, Feelders R, et al. The multi-ligand somatostatin analogue SOM230 inhibits ACTH secretion by cultured human corticotroph adenomas via somatostatin receptor type 5. Eur J Endocrinol. 2005;152:645–54. doi:10.1530/eje.1.01876.PubMed

80.

Boscaro M, Atkinson A, Bertherat J, et al. SOM230 Cushing’s disease study group. Early data on the efficacy and safety of the novel multi-ligand somatostatin analog, SOM230, in patients with Cushing’s disease. Presented at the 87th Annual Meeting of the Endocrine Society. San Diego (CA), June 4–7, 2005.

81.

Pivonello R, Ferone D, Lamberts SW, Colao A. Cabergoline plus lanreotide for ectopic Cushing’s syndrome. N Engl J Med. 2005;352:2457–8. doi:10.1056/NEJM200506093522322.PubMed

82.

Colao A, Di Sarno A, Marzullo P, Di Somma C, Cerbone G, Landi ML, et al. New medical approaches in pituitary adenomas. Horm Res. 2000;53(Suppl 3):76–87. doi:10.1159/000023539.PubMed

83.

Bevan JS, Burke CW. Non-functioning pituitary adenomas do not regress during bromocriptine therapy but possess membrane-bound dopamine receptors which bind bromocriptine. Clin Endocrinol (Oxf). 1986;25:561–72. doi:10.1111/j.1365-2265.1986.tb03610.x.

84.

Pivonello R, Matrone C, Filippella M, Cavallo LM, Di Somma C, Cappabianca P, et al. Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment. J Clin Endocrinol Metab. 2004;89:1674–83. doi:10.1210/jc.2003-030859.PubMed

85.

Ferone D, Lastoria S, Colao A, Varrella P, Cerbone G, Acampa W, et al. Correlation of scintigraphic results using ¹²³I-methoxybenzamide with hormone levels and tumor size response to quinagolide in patients with pituitary adenomas. J Clin Endocrinol Metab. 1998;83:248–52. doi:10.1210/jc.83.1.248.PubMed

86.

Hedner P, Valdemarsson S. Reduced size of a hormonally silent pituitary adenoma during treatment with CV 205–502, a new dopamine agonist mainly stimulating D₂ receptors. Neurosurgery. 1989;25:948–50. doi:10.1097/00006123-198912000-00015.PubMed

87.

Kwekkboom DJ, Lamberts SWJ. Long-term treatment with dopamine agonist CV 205–502 of patients with clinically non-functioning, gonadotroph, or α-subunit secreting pituitary adenoma. Clin Endocrinol (Oxf). 1992;36:171–17. doi:10.1111/j.1365-2265.1992.tb00953.x.

88.

Colao A, Ferone D, Lastoria S, Cerbone G, Di Sarno A, Di Somma C, et al. Hormone levels and tumor size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically nonfunctioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. Clin Endocrinol (Oxf). 2000;52:437–45. doi:10.1046/j.1365-2265.2000.00951.x.

89.

Ikuyama S, Nawata H, Kato K, Karashima T, Ibayashi H, Nakagaki H. Specific somatostatin receptors on human pituitary adenoma cell membranes. J Clin Endocrinol Metab. 1985;61:98–103.

90.

Reubi JC, Heitz PU, Landolt AM. Visualization of somatostatin receptors and correlation with immunoreactive growth hormone and prolactin in human pituitary adenomas: evidence for different tumor subclasses. J Clin Endocrinol Metab. 1987;65:65–73.PubMedCrossRef

91.

Greenman Y, Melmed S. Heterogeneous expression of two somatostatin receptor subtypes in pituitary tumors. J Clin Endocrinol Metab. 1994;78:398–403. doi:10.1210/jc.78.2.398.PubMed

92.

Faglia G, Bazzoni N, Spada A, Arosio M, Ambrosi B, Spinelli F, et al. In vivo detection of somatostatin receptors in patients with functionless pituitary adenomas by means of a radio-iodinated analog of somatostatin. J Clin Endocrinol Metab. 1991;73:850–6. (¹²³I)SDZ204–090.PubMed

93.

Plockinger U, Reichel M, Fett U, Saeger W, Quabbe HJ. Preoperative octreotide treatment of growth hormone-secreting and clinically nonfunctioning pituitary macroadenomas: effect on tumor volume and lack of correlation with immunohistochemistry and somatostatin receptor scintigraphy. J Clin Endocrinol Metab. 1994;79:1416–23. doi:10.1210/jc.79.5.1416.PubMed

94.

Lamberts SWJ, de Herder WW, van der Lely AJ, Hofland LJ. Imaging and medical management of clinically nonfunctioning pituitary tumors. Endocrinologist. 1995;5:448–51. doi:10.1097/00019616-199511000-00020.

95.

Colao A, Lastoria S, Ferone D, Varrella P, Marzullo P, Pivonello R, et al. Pituitary uptake of In-111-DTPA-D-Phe¹-octreotide in the normal pituitary and in pituitary adenomas. J Endocrinol Invest. 1999;22:176–83.PubMed

96.

Borson-Chazot F, Houzard C, Ajzenberg C, Nocaudie M, Duet M, Mundler O, et al. Somatostatin receptor imaging in somatotroph and non-functioning pituitary adenomas: correlation with hormonal and visual responses to octreotide. Clin Endocrinol (Oxf). 1997;47:589–98. doi:10.1046/j.1365-2265.1997.3361119.x.

97.

Warnet A, Harris AG, Renard E, Martin D, James-Deidier A, Chaumet-Riffaud P, and the French multicenter octreotide study group. A prospective multicenter trial of octreotide in 24 patients with visual defects caused by nonfunctioning and gonadotropin-secreting pituitary adenomas. Neurosurgery 1997;41:786–97. doi:10.1097/00006123-199710000-00005.PubMed

98.

Gasperi M, Petrini L, Pilosu R, Nardi M, Marcello AA, Mastio F, et al. Octreotide treatment does not affect the size of most non-functioning pituitary adenomas. J Endocrinol Invest. 1993;16:541–3.PubMed

99.

De Bruin TWA, Kwekkeboom DJ, van't Verlaat JW, Reubi JC, Krenning EP, Lamberts SW, Croughs RJ. Clinically nonfunctioning pituitary adenoma and octreotide response to long term high dose treatment, and studies in vitro. J Clin Endocrinol Metab. 1992;75:1310–7.PubMed

100.

Klibanski A, Alexander JM, Bikkal HA, Hsu DW, Swearingen B, Zervas NT. Somatostatin regulation of glycoprotein hormone and free subunit secretion in clinically nonfunctioning and somatotroph adenomas in vitro. J Clin Endocrinol Metab. 1991;73:1248–55.PubMed

101.

Katznelson L, Oppenheim DS, Coughlin JF, Kliman B, Schoenfeld DA, Klibanski A. Chronic somatostatin analog administration in patients with a-subunit-secreting pituitary tumors. J Clin Endocrinol Metab. 1992;75:1318–25. doi:10.1210/jc.75.5.1318.PubMed

102.

Andersen M, Bjerre P, Schrøder HD, Edal A, Høilund-Carlsen PF, Pedersen PH, et al. In vivo secretory potential and the effect of combination therapy with octreotide and cabergoline in patients with clinically non-functioning pituitary adenomas. Clin Endocrinol (Oxf). 2001;54:23–30. doi:10.1046/j.1365-2265.2001.01172.x.

103.

Colao A, Martino E, Cappabianca P, Cozzi R, Scanarini M, Ghigo E, A.L.I.C.E. Study Group. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 2006;29:1017–20.PubMed

Title: Medical therapy of pituitary adenomas: Effects on tumor shrinkage
Authors: Annamaria Colao
Rosario Pivonello
Carolina Di Somma
Silvia Savastano
Ludovica F. S. Grasso
Gaetano Lombardi
Publication date: 01-06-2009
Publisher: Springer US
Published in: Reviews in Endocrine and Metabolic Disorders / Issue 2/2009
Print ISSN: 1389-9155
Electronic ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-008-9107-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2009

Somatostatin and dopamine receptors as targets for medical treatment of Cushing’s Syndrome

Modern techniques for pituitary radiotherapy

Advantages and disadvantages of GH/IGF-I combination treatment

Potential role of type I interferons in the treatment of pituitary adenomas

Potential of retinoic acid derivatives for the treatment of corticotroph pituitary adenomas

Growth hormone receptor modulators

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage